文献速递类风湿关节炎脊柱关节炎

围手术期使用TNF抑制剂不影响炎性关节炎患者全髋关节置换术的假体生存:一项基于登记资料的队列研究

Perioperative treatment with TNF inhibitors does not affect survival of total hip arthroplasty in inflammatory arthritis: A registry-based cohort study.
PubMed 文献 · Semin Arthritis Rheum · 2023-03-31

该研究基于RIPO登记资料回顾性分析2008至2019年全髋关节置换术,比较围手术期使用TNF抑制剂、未使用bDMARD/tsDMARD的炎性关节炎患者及骨关节炎对照的假体生存。平均随访5年,三组以任何翻修手术为终点的生存率无显著差异,翻修比例分别为2.5%、3%和0.8%,术后感染或无菌性松动风险亦无显著差异。

要点

  • 围手术期使用TNF抑制剂与未使用bDMARD/tsDMARD的炎性关节炎患者相比,翻修手术生存率无显著差异(p=0.713)。
  • TNF抑制剂组与骨关节炎对照组相比,翻修手术生存率亦无显著差异(p=0.123)。
  • 三组术后感染或无菌性松动的风险无显著差异。

核心结论

  • 围手术期使用TNF抑制剂的炎性关节炎患者,翻修手术风险未增加,结果支持该类药物对假体植入物长期生存的安全性。

研究设计与样本

  • 基于RIPO登记资料的回顾性分析,纳入2008至2019年施行的全髋关节置换术,并与行政数据库交叉匹配识别类风湿关节炎、银屑病关节炎、强直性脊柱炎、原发性骨关节炎及目标治疗。

主要发现

  • 平均随访5年,围手术期使用TNF抑制剂者与未使用bDMARD/tsDMARD者相比,以任何翻修手术为终点的生存率无显著差异(p=0.713)。
  • TNF抑制剂组与骨关节炎对照组相比,以任何翻修手术为终点的生存率无显著差异(p=0.123)。
  • 截至最近一次随访,TNF抑制剂组2.5%的患者、未使用bDMARD/tsDMARD组3%的患者、骨关节炎组0.8%的患者接受了翻修手术。
  • 三组术后感染或无菌性松动的风险无显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Aim of this study was to investigate the effect of perioperative exposure to TNF inhibitors (TNFi) on the long-term survival of total hip arthroplasty (THA) in inflammatory arthritis patients from a large regional register of arthroplasty procedures (RIPO). METHODS: This study is a retrospective analysis of data from RIPO for THAs performed between 2008 and 2019. After extraction of the procedures of interest from the RIPO dataset, cross-matching with administrative databases were used to identify patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), primary osteoarthritis (OA), and treatments of interest. Three different cohorts of patients were identified: perioperative TNFi-treated patients (6 months before or after the surgery), perioperative non-bDMARD/tsDMARD (biologic or targeted-synthetic disease modifying antirheumatic drugs), and OA. RESULTS: At an average follow-up of 5 years, survival rates (using any revision surgery as an endpoint) were not significantly different when perioperative TNFi users and non-bDMARD/tsDMARD patients were compared (p = 0.713), and between TNFi-treated and OA controls (p = 0.123). At the latest available follow-up, 2.5% patients in the TNFi cohort, 3% in the non-bDMARD/tsDMARD cohort, and 0.8% in the OA cohort underwent revision surgery. No significant differences were found comparing the risk of postoperative infection or aseptic loosening among groups. CONCLUSION: Risk of revision surgery is not increased in patients with inflammatory arthritis perioperatively exposed to TNFi. Our results support the long-term safety of this class of molecules on survival of prosthetic implants.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Di Martino A, Ursini F, Bordini B, et al. Perioperative treatment with TNF inhibitors does not affect survival of total hip arthroplasty in inflammatory arthritis: A registry-based cohort study. Semin Arthritis Rheum. 2023. PMID: 37028127. doi:10.1016/j.semarthrit.2023.152201

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。